Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADVR:THE NEW COMPANY...WITH A NEW LIFE...AND A NEW MISSION -- Ignore unavailable to you. Want to Upgrade?

To: DAN LITTLE who wrote (349)	6/9/1998 2:10:00 PM
From: DAN LITTLE	Respond to of 4891

This is easier sorry I didn't catch it the first time. That last link for Lancet is just a brief discription. This one is to subscribe. Dan thelancet.com

To: DAN LITTLE who wrote (349)	6/9/1998 2:52:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4891

Seems like an antiviral study was recently published there. Maybe they will do a follow-up? The viral load is a measure of the levels of HIV. The goal of HIV treatment is to reduce the viral load and to help the immune system to renew itself. The French study, published in The Lancet medical journal, showed that restored immunity depends on the amount and duration of the decrease in the viral-load and a corresponding increase of CD4 T cells. Message 4754722